These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30904558)

  • 1. Real-World Prevalence of Adverse Events After Initiating Sacubitril/Valsartan Compared With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Systolic Heart Failure.
    Adie S; Bitar A; Hanigan S; Pogue K; Koelling T; Dorsch M
    J Card Fail; 2019 May; 25(5):412-413. PubMed ID: 30904558
    [No Abstract]   [Full Text] [Related]  

  • 2. Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance.
    Kim YS; Brar S; D'Albo N; Dey A; Shah S; Ganatra S; Dani SS
    Cardiovasc Drugs Ther; 2022 Oct; 36(5):915-924. PubMed ID: 34125356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevant adverse events and drug discontinuation of sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry.
    Matsumoto S; McMurray JJV; Nasu T; Ishii S; Kagiyama N; Kida K; Fujimoto W; Kikuchi A; Ijichi T; Shibata T; Ikeda T; Kanaoka K
    J Cardiol; 2024 Aug; 84(2):133-140. PubMed ID: 38000538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Life Threatening Angioedema Due to Valsartan/Sacubitril With Previously Well-Tolerated ACE Inhibitor.
    Raheja H; Kumar V; Kamholz S; Hollander G; Shani J
    Am J Ther; 2018; 25(4):e508-e509. PubMed ID: 28452844
    [No Abstract]   [Full Text] [Related]  

  • 5. The real-world safety of sacubitril / valsartan among older adults (≥75): A pharmacovigilance study from the FDA data.
    Lerman TT; Greenberg N; Fishman B; Goldman A; Talmor-Barkan Y; Bauer M; Goldberg I; Goldberg E; Kornowski R; Krause I; Levi A; Cohen E
    Int J Cardiol; 2024 Feb; 397():131613. PubMed ID: 38030039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors.
    Norberg H; Bergdahl E; Lindmark K
    Cardiovasc Ther; 2019; 2019():6745074. PubMed ID: 31772613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort.
    López-Azor JC; Vicent L; Valero-Masa MJ; Esteban-Fernández A; Gómez-Bueno M; Pérez Á; Díez-Villanueva P; De-Juan J; Manuel-Iniesta Á; Bover R; Del Prado S; Martínez-Sellés M
    ESC Heart Fail; 2019 Dec; 6(6):1161-1166. PubMed ID: 31701680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new class of drugs for systolic heart failure: The PARADIGM-HF study.
    Sabe MA; Jacob MS; Taylor DO
    Cleve Clin J Med; 2015 Oct; 82(10):693-701. PubMed ID: 26469827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.
    Shi V; Senni M; Streefkerk H; Modgill V; Zhou W; Kaplan A
    Int J Cardiol; 2018 Aug; 264():118-123. PubMed ID: 29776559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
    Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV
    Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacubitril/Valsartan and Mexiletine: A Proarrhythmic Combination?
    Weir RAP
    Cardiology; 2019; 142(1):4-6. PubMed ID: 30852576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacubitril/Valsartan (Entresto) for Heart Failure.
    Cheng J
    Am Fam Physician; 2016 Oct; 94(8):611-612. PubMed ID: 27929235
    [No Abstract]   [Full Text] [Related]  

  • 14. Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results.
    Owens RE; Oliphant CS
    J Am Board Fam Med; 2017; 30(4):556-557. PubMed ID: 28720639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic.
    Pogge EK; Davis LE
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):143-151. PubMed ID: 29455335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
    Rodgers JE
    Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neprilysin Inhibitors: Emerging Therapy for Heart Failure.
    Owens AT; Brozena S; Jessup M
    Annu Rev Med; 2017 Jan; 68():41-49. PubMed ID: 27686019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacubitril/Valsartan-Associated Small Bowel Ileus.
    Hanefeld-Fox L; Jimenez L; Heflin R; Quiel L
    Am J Ther; 2018; 25(6):e705-e706. PubMed ID: 29324464
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis.
    Martins E Pereira G; S Duarte G; Katerenchuk V; Costa J; David C; Ferreira JJ; Pinto FJ; Caldeira D
    Expert Opin Drug Saf; 2021 May; 20(5):577-588. PubMed ID: 33459086
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
    Desai AS; Solomon S; Claggett B; McMurray JJ; Rouleau J; Swedberg K; Zile M; Lefkowitz M; Shi V; Packer M
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.